Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | ESR1 | P03372 | 3/20 | 0.75 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.75 |
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9126141 | 0.89 | LMNA (0.73) | MAPTLMNAESR1ESR2HTT | |
| SCHEMBL132367 | 0.89 | LMNA (0.73) | MAPTLMNAESR1ESR2HTT | |
| SCHEMBL3842531 | 0.89 | LMNA (0.73) | MAPTLMNAESR1ESR2HTT | |
| SCHEMBL29984922 | 0.87 | LMNA (0.70) | MAPTLMNAESR1ESR2HTT | |
| SCHEMBL18423 | 0.87 | LMNA (1.00) | MAPTLMNAESR1ESR2HTT | |
| SCHEMBL699850 | 0.87 | LMNA (1.00) | MAPTLMNAESR1ESR2HTT | |
| SCHEMBL29825996 | 0.85 | CES2 (0.80) | MAPTLMNAESR1ESR2HTT | |
| Ethylene SCHEMBL10490014 | 0.84 | LMNA (0.67) | MAPTLMNAESR1ESR2HTT | |
| SCHEMBL7929114 | 0.84 | LMNA (0.94) | MAPTLMNAESR1ESR2HTT | |
| Methane SCHEMBL6378712 | 0.84 | LMNA (0.94) | MAPTLMNAESR1ESR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| EP-4450490-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | Prazer Therapeutics Inc. (KR) | 2024-10-23 | — | — | EP | disclosed |
| CN-118382620-A | Novel compounds for degrading target proteins or polypeptides by multiple ubiquitination | 普瑞泽治疗公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2024008909-A1 | INHIBITORS OF CORONAVIRUS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-11 | — | — | WO | disclosed |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| WO-2023113457-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | (주)프레이저테라퓨틱스 | 2023-06-22 | — | — | WO | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| CN-109415313-B | Novel arylethene derivative and pharmaceutical composition containing the same as active ingredient | 诺麦塔制药有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-109563054-B | Novel arylethene derivative and pharmaceutical composition containing same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2022-08-05 | — | — | CN | disclosed |
| CN-114685505-A | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-0410359-B1 | Substituted aminoalkoxy-benzene-derivatives | HOFFMANN LA ROCHE (CH) | 1994-01-26 | — | — | EP | disclosed |
| US-5214046-A | Synergistic mixtures, inhibitors of sterol biosynthesis | HOFFMANN-LA ROCHE INC. (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0222536-B1 | AROMATIC POLYMER AND PROCESS FOR ITS PREPARATION | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-01-20 | — | — | EP | disclosed |
| EP-0182648-B1 | PROCESS FOR THE PREPARATION OF POLYETHERKETONES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-08-12 | — | — | EP | disclosed |
| US-5106878-A | Synergistic effects with other fungicides | HOFFMANN-LA ROCHE INC. (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0410359-A1 | Substituted aminoalkoxy-benzene-derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1991-01-30 | — | — | EP | disclosed |
| US-4950729-A | AROMATIC POLYETHERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-21 | — | — | US | disclosed |
| US-4711945-A | Polyketone | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-12-08 | — | — | US | disclosed |
| EP-0222536-A2 | Aromatic polymer and process for its preparation | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-20 | — | — | EP | disclosed |
| EP-0182648-A2 | Process for the Preparation of Polyetherketones | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | MAPT 3052/4885LMNA 4330/4885ESR1 4437/4885 |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | MAPT 561/4885LMNA 2751/4885ESR1 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.